sure a tremendous benefit of leronlimab efficacy is that lernoimab amplifies available ICU resources.

i imagine the fda would approve anything which deomonstrates icu resource amplification for covid.

i made my post becaue i couldnt understand how improved ventilator anesthisia has any connection to leronlimab.

i dont understand the logic of "if the fda approves ventilator anesthesia", then something will happen with leronlimab.

i cant see the connection between the event of the fda approving a ventilator anesthesia and any fda event on leronlimab.

better ventilator anesthesia is a good thing, espcially with covid. i expect the fda would examine the merits of ventilator anesthesia separately from other treatments of covid.

in my view, the fda just doesn't see leronlimab as passing the mathematical bar that has been set.

while i might disagree with the fda's conclusion, i still see the fda's actions on leronlimab as not related to any of the fda's actions on ventilator anesthesia.